1Tamargo J, Delpon E, Caballero R. The safety of digoxin as a pharmacological treatment of atrial fibrillation[J]. Expert Opin Drug Saf, 2006, 5(3): 453-467.
2Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation ( from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [ AFFIRM] Study) [J]. Am J Cardiol, 2004, 93(10): 1247-1253.
3Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation [J]. NEnglJ Med, 2010, 362(15):1363-1373.
4Rojas-Fernandez CH, Viana L, Dadfar F. Contemporary considerations for the use of digoxin for heart failure in older patients[J]. Can Pharm J, 2011, 144:265-269.
5Siu CW, Lau CP, Lee WL, et al. Intravenous diltiazem is superior to intravenous amiodarone or ctigoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation [J]. Crit Care Med, 2009, 37 (7): 2174-2179.
6Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation:a clinical practice guideline from theAmerican Academy of Family Physicians and the American College of Physicians[J]. Ann Intern Med, 2003, 139(12) 1009-1017.
7Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study[J]. Eur Heart J, 2012, Nav27[Epudahead print].
8Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data[J]. Heart, 2008, 94(2): 191-196.
9Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation[J]. Heart Rhythm, 2005, 2(5):525-529.
10Bianconi L, Mennuni M. Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial[J]. Am J Cardiol, 1998, 82(5) : 584-588.
